Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDYN antisense RNA 1 (PDYN-AS1)
- Target
- PDYN-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01
Overview
PDYN antisense RNA 1 (PDYN-AS1) is a long non-coding RNA transcribed from the antisense strand of the prodynorphin gene locus. Antisense lncRNAs, like PDYN-AS1, can regulate their sense gene counterparts through a variety of mechanisms, including modification of chromatin state, transcriptional interference, and mRNA stability, often by forming double-stranded RNA intermediates[6]. While the detailed function and disease involvement of PDYN-AS1 itself are not fully characterized, analogous antisense lncRNAs are known to play roles in controlling gene expression in the nervous system and may be implicated in epigenetic regulation of neuropeptide gene transcription[1][5]. There is currently no information on PDYN-AS1 as a direct drug target, and no therapeutic interventions interact specifically with it.
- Other names
- PDYN antisense RNA 1PDYN-AS1
02
Mechanism of action
Not applicable; There are no drugs with mechanisms of action targeting PDYN-AS1.
03
Biological functions
Regulation of gene expression at the transcriptional and post-transcriptional levelsPotential chromatin remodeling and epigenetic regulation through formation of RNA duplexes or recruitment of epigenetic modifiers
04
Disease associations
Currently, no direct disease involvement for PDYN-AS1 has been published, but dysregulation of antisense transcripts is being investigated in various neurological and psychiatric conditions by analogy with other NATs
05
Safety considerations
No notable safety concerns or therapeutic challenges are described, as PDYN-AS1 is not a pharmacological target.
06
Biomarkers
No established biomarkers for patient selection or efficacy monitoring are reported for PDYN-AS1.
Beyond the preview
Go deeper on PDYN antisense RNA 1 (PDYN-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDYN antisense RNA 1 (PDYN-AS1).